Alivus Life Sciences Ltd Share Price
(ALIVUS)
₹1090.7▲3.8%
as on 04:01PM, 29 Apr 2025
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 5.5 % |
3 Month Return | -6.54 % |
1 Year Return | + 31.58 % |
Market Stats | |
Previous Close | ₹1,050.80 |
Open | ₹1,060.00 |
Volume | 3.36L |
Upper Circuit | ₹1,260.90 |
Lower Circuit | ₹840.70 |
Market Cap | ₹13,365.12Cr |
P/E Ratio
0PEG Ratio
0Market Cap
₹13,365.12 Cr
P/B Ratio
4.07
EPS
0Dividend Yield
0Sector
Pharmaceuticals
ROE
21.07
based on 4 analysts
80.00%
Buy
20.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Glenmark Life Sciences. An average target of ₹1296.25
Source: S&P Global Market Intelligence
Glenmark Life Sciences price forecast by 4 analysts
Upside of18.85%
High
₹1360
Target
₹1296.25
Low
₹1150
Glenmark Life Sciences target price ₹1296.25, a slight upside of 18.85% compared to current price of ₹1090.7. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Life Sciences revenue growth forecast
Expected growth rate Q1, FY2027:0
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Life Sciences EPS growth forecast
EPS estimate Q1, FY2027:0
Forecast
Actual
Source: S&P Global Market Intelligence
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 7 days, ALIVUS stock has moved up by 2.6%
MF Holding Up
Mutual Funds have increased holdings from 3.23% to 3.59% in Mar 2025 quarter
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 15.9%
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 22.8%
Promoter Holding Down
Promoters have decreased holdings from 75.00% to 74.99% in Mar 2025 quarter
FII Holding Down
Foreign Institutions have decreased holdings from 6.74% to 6.57% in Mar 2025 quarter
Retail Holding Down
Retail Investor have decreased holdings from 13.40% to 13.25% in Mar 2025 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 74.99% | 0.00 | |
Foreign Institutions | 6.57% | 0.00 | |
Mutual Funds | 3.59% | 0.00 | |
Retail Investors | 13.25% | 0.00 | |
Others | 1.59% | 0.00 |
Alivus Life Sciences Ltd’s net profit jumped 15.32% since last year same period to ₹136.96Cr in the Q3 2024-2025. On a quarterly growth basis, Alivus Life Sciences Ltd has generated 43.68% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending September 2023, Alivus Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 3.99%.
Read More about DividendsBearish
Neutral
Bullish
Alivus Life Sciences Ltd is currently in a Bullish trading position according to technical analysis indicators.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹13,365.12 Cr | 9.14% | 0.51 | NA | NA | |
NA | ₹147.07 Cr | 35.43% | 0.62 | NA | NA | |
NA | ₹5,411.31 Cr | 432.02% | 0.50 | ₹33 Cr | ₹204 Cr | |
NA | ₹1,510.04 Cr | 381.87% | 0.52 | NA | NA | |
NA | ₹3,596.41 Cr | 157.18% | 0.51 | NA | NA |
Organisation | Glenmark Life Sciences |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Alivus Life Sciences Ltd share price today stands at ₹1090.7, Open: ₹1060, Previous Close: ₹1050.8, High: ₹1109, Low: ₹1055.2, 52 Week High: ₹1335.1, 52 Week Low: ₹743.85.
Today's traded volume of Alivus Life Sciences Ltd(ALIVUS) is 3.36L.
Today's market capitalisation of Alivus Life Sciences Ltd(ALIVUS) is ₹13365.12Cr.
Alivus Life Sciences Ltd (ALIVUS) share price is ₹1090.7. It is down -18.31% from its 52 Week High price of ₹1335.1
Alivus Life Sciences Ltd (ALIVUS) share price is ₹1090.7. It is up 46.63% from its 52 Week Low price of ₹743.85